Response to letter regarding article "Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease"

Am Heart J. 2020 May:223:111-112. doi: 10.1016/j.ahj.2020.03.002. Epub 2020 Mar 7.

Authors

Matthew R Weir¹, Veronica Ashton², Kenneth T Moore³, Shubham Shrivastava⁴, Eric D Peterson⁵, Eric M Ammann²

Affiliations

¹ University of Maryland School of Medicine, Baltimore, 21201 MD. Electronic address: [email protected].
² Janssen Scientific Affairs, Titusville, NJ.
³ Janssen Medical Affairs, Titusville, NJ.
⁴ Mu Sigma, Bangalore, India.
⁵ Duke University School of Medicine, Durham, NC.

PMID: 32386598
DOI: 10.1016/j.ahj.2020.03.002

No abstract available

Publication types

Letter
Comment

MeSH terms

Anticoagulants
Atrial Fibrillation*
Factor Xa Inhibitors
Humans
Renal Insufficiency, Chronic*
Rivaroxaban
Warfarin

Substances

Anticoagulants
Factor Xa Inhibitors
Warfarin
Rivaroxaban